These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 23254896)

  • 1. Where vaptans do and do not fit in the treatment of hyponatremia.
    Jovanovich AJ; Berl T
    Kidney Int; 2013 Apr; 83(4):563-7. PubMed ID: 23254896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.
    Gargani L; Schmidt PH; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1505-13. PubMed ID: 22103869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options.
    Jao GT; Chiong JR
    Clin Cardiol; 2010 Nov; 33(11):666-71. PubMed ID: 21089110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vasopressin antagonists in treatment of hyponatremia].
    Olszewski W; Głuszek J
    Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet.
    Gross PA; Wagner A; Decaux G
    Kidney Int; 2011 Sep; 80(6):594-600. PubMed ID: 21451459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyponatremia and the use of vasopressin receptor antagonists in critically ill patients.
    Lehrich RW; Greenberg A
    J Intensive Care Med; 2012; 27(4):207-18. PubMed ID: 21571754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of vasopressin receptor antagonists in hyponatremia.
    Elhassan EA; Schrier RW
    Expert Opin Investig Drugs; 2011 Mar; 20(3):373-80. PubMed ID: 21320003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of vaptans in the management of hyponatremia.
    Lehrich RW; Ortiz-Melo DI; Patel MB; Greenberg A
    Am J Kidney Dis; 2013 Aug; 62(2):364-76. PubMed ID: 23725974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic use of vaptans for the treatment of dilutional hyponatremia.
    Cassagnol M; Shogbon AO; Saad M
    J Pharm Pract; 2011 Aug; 24(4):391-9. PubMed ID: 21813818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
    Soupart A; Coffernils M; Couturier B; Gankam-Kengne F; Decaux G
    Clin J Am Soc Nephrol; 2012 May; 7(5):742-7. PubMed ID: 22403276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of "Vaptans" in treatment of hyponatremia].
    Tanındı A; Töre HF
    Turk Kardiyol Dern Ars; 2015 Apr; 43(3):292-301. PubMed ID: 25906004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on tolvaptan for the treatment of hyponatremia.
    Dasta JF; Chiong JR; Christian R; Friend K; Lingohr-Smith M; Lin J; Cassidy IB
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):399-410. PubMed ID: 22971027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
    Dahl E; Gluud LL; Kimer N; Krag A
    Aliment Pharmacol Ther; 2012 Oct; 36(7):619-26. PubMed ID: 22908905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaptans for the treatment of hyponatremia.
    Robertson GL
    Nat Rev Endocrinol; 2011 Mar; 7(3):151-61. PubMed ID: 21283124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of 3% saline vs. conivaptan in achieving hyponatremia treatment goals.
    Dominguez M; Perez JA; Patel CB
    Methodist Debakey Cardiovasc J; 2013; 9(1):49-53. PubMed ID: 23519387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyponatremia in heart failure.
    Farmakis D; Filippatos G; Parissis J; Kremastinos DT; Gheorghiade M
    Heart Fail Rev; 2009 Jun; 14(2):59-63. PubMed ID: 18758941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaptans: a potential new approach for treating chronic hyponatremia in psychotic patients.
    Josiassen RC; Curtis JL; Shaughnessy RA; Filmyer DM; Geboy AG; Skuban N; Ouyang J; Czerwiec F
    Clin Schizophr Relat Psychoses; 2012 Apr; 6(1):21-6. PubMed ID: 22453866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience.
    Pose E; Solà E; Piano S; Gola E; Graupera I; Guevara M; Cárdenas A; Angeli P; Ginès P
    Am J Med; 2017 Mar; 130(3):372-375. PubMed ID: 27746291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current options of treatment of hyponatremia].
    Tesař V
    Vnitr Lek; 2016; 62 Suppl 6():97-101. PubMed ID: 28124939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.